Stockreport

Rodman & Renshaw Initiates Biomea Fusion (BMEA) at Buy with $8 Price Target [Yahoo! Finance]

Biomea Fusion, Inc.  (BMEA) 
PDF In Q3 2025, Biomea announced that the company was shifting its strategy to focus on its two primary assets: icovamenib, a menin inhibitor for type 2 diabetes/T2D, and B [Read more]